Following the rationale that three FAM20C substrates (CP, APOE, AFP) were identified as potential HIE biomarkers based on their progressively increasing/decreasing expression patterns across four clinical subgroups (control, mild HIE, moderate HIE, severe HIE), which could enhance their diagnostic utility for HIBD‐induced neurodysplasia, FAM20C is consequently proposed as a putative therapeutic target for neurodevelopmental disorders associated with HIBD. The gene discussed is CP; the disease is neurodevelopmental disorder.